<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vancomycin-resistant enterococci: Epidemiology, prevention, and control</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vancomycin-resistant enterococci: Epidemiology, prevention, and control</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vancomycin-resistant enterococci: Epidemiology, prevention, and control</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deverick J Anderson, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony Harris, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vancomycin-resistant enterococci (VRE) are a common and difficult-to-treat cause of hospital-acquired infection. The epidemiology of VRE and strategies for preventing its spread will be reviewed here. The infection control measures described are applicable to all resistant enterococci.</p><p>The mechanisms of <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> resistance, infections caused by VRE, and the treatment of VRE are discussed separately. (See  <a class="medical medical_review" href="/d/html/470.html" rel="external">"Mechanisms of antibiotic resistance in enterococci"</a> and  <a class="medical medical_review" href="/d/html/3160.html" rel="external">"Microbiology of enterococci"</a> and  <a class="medical medical_review" href="/d/html/3163.html" rel="external">"Treatment of enterococcal infections"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> inhibits enterococci by binding to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of cell wall precursors, compromising the subsequent enzymatic steps in the synthesis of cell wall. High-level resistance to vancomycin is encoded by different clusters of genes referred to as the vancomycin-resistance gene clusters (eg, <em>vanA</em>, <em>vanB</em>, and <em>vanD</em> gene clusters).</p><p>The end result is the replacement of D-Ala-D-Ala-ending peptidoglycan precursors with D-alanyl-D-lactate termini, to which <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> binds with significantly lower affinity. The replacement of D-alanine by D-lactate, which disrupts one of the five hydrogen bonds required for the interaction of vancomycin with its target, increases the minimum inhibitory concentration (MIC) of vancomycin almost 1000-fold. (See  <a class="medical medical_review" href="/d/html/470.html" rel="external">"Mechanisms of antibiotic resistance in enterococci", section on 'Vancomycin resistance'</a>.)</p><p>The Clinical and Laboratory Standards Institute has issued the following MIC definitions for <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> susceptibility and resistance in enterococci [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> susceptible – ≤4 mcg/mL</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> resistant – ≥32 mcg/mL</p><p></p><p>An MIC of 8 to 16 mcg/mL was considered <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> intermediate, but we do not recommend vancomycin therapy for such isolates.</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Colonization and clinical infection with VRE were first described in Europe in the 1980s [<a href="#rid2">2,3</a>] and soon thereafter in the United States [<a href="#rid4">4</a>]. The presence of VRE in Europe was related to the use of glycopeptides such as avoparcin as a food additive for growth promotion in animals for more than 20 years, a practice that was subsequently banned by the European Union.</p><p>Multiple epidemics of VRE infection have been described in diverse hospital settings (eg, medical and surgical intensive care units, and medical and pediatric wards) and, like methicillin-resistant <em>Staphylococcus aureus</em>, VRE is endemic in many large hospitals [<a href="#rid5">5-12</a>]. In 2008, the National Healthcare Safety Network (NHSN) published summary data on multidrug-resistant organisms suggesting that <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> resistance had increased to 33 percent among enterococci that caused health care-associated infections in 2006 and 2007 [<a href="#rid13">13</a>]. In fact, the rate of hospitalization with VRE essentially doubled during 2003 to 2006 from 4.60 to 9.48 hospitalizations per 100,000 population [<a href="#rid14">14</a>]. </p><p>During the 2010s, epidemiologic trends varied with geography. In a review of trends from 890 United States hospitals and more than 41 million hospitalizations between 2012 and 2017, the incidence of VRE among hospitalized patients declined 39.2 percent, while the incidence of hospital-onset VRE declined 48.8 percent [<a href="#rid15">15</a>]. In contrast, a review of one million hospitalizations from 70 Canadian hospitals between 2014 and 2018 demonstrated a 148 percent increase in VRE infections [<a href="#rid16">16</a>].</p><p>Modern techniques have expanded our knowledge of the epidemiology of VRE. For example, pulsed-field gel electrophoresis (PFGE) has been utilized in analyses of both epidemic and endemic clusters of VRE infection and colonization [<a href="#rid3">3,5,8,17,18</a>]. These studies demonstrated that a single VRE clone can spread within an institution or a patient care unit. In fact, reports have demonstrated that these clonal outbreaks can persist for three to four years within an institution [<a href="#rid19">19,20</a>]. In addition, VRE strains can transfer resistance horizontally to unrelated strains. Both methods of spread can occur simultaneously in a single institution. One report using PFGE found 45 different profiles in a single medical center where VRE had become endemic [<a href="#rid3">3</a>].</p><p>The vast majority of VRE isolates are <em>Enterococcus faecium</em>. This was illustrated in a prospective analysis from the Surveillance and Control or Pathogens of Epidemiologic Importance (SCOPE) database of 24,179 nosocomial bloodstream infections occurring in 49 hospitals in the United States between 1995 and 2002 [<a href="#rid21">21</a>]. <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> resistance was found in 60 percent of <em>E. faecium</em> isolates compared with 2 percent of <em>E. faecalis</em> isolates. Data from the NHSN suggest that resistance trends are worsening; 80 percent of the 987 isolates of <em>E. faecium</em> and 6.9 percent of the 1497 isolates of <em>E. faecalis</em> reported in 2006 and 2007 were vancomycin resistant [<a href="#rid13">13</a>].</p><p>VRE colonization frequently leads to subsequent infection. A systematic review and meta-regression of 14 studies concluded that 8 percent of patients with VRE colonization develop infection within 30 days [<a href="#rid22">22</a>]. VRE infections have been associated with adverse outcomes. The magnitude of this effect was illustrated in a meta-analysis of nine studies of 1614 enterococcal bloodstream infections, 42 percent of which were due to VRE [<a href="#rid23">23</a>]. The mortality rate was significantly higher in patients with VRE compared with vancomycin-susceptible enterococcal isolates (summary odds ratio 2.5, 95% CI 1.9-3.4).</p><p class="headingAnchor" id="H4"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>After vancomycin-resistant enterococci (VRE) have been introduced into a health care setting, transmission is determined by selective pressure due to antimicrobial use, the proportion of colonized patients, the availability of susceptible patients, and adherence to prevention efforts [<a href="#rid24">24</a>]. The risk increases significantly in an intensive care unit once the proportion of patients exceeds 50 percent.</p><p>VRE colonize the gastrointestinal tract and can be found on the skin due to fecal shedding. Colonization with VRE generally precedes infection, but not all patients with colonization become infected. Persons either colonized or infected with VRE can serve as sources for secondary transmission.</p><p>VRE colonization is identified through the use of rectal or perirectal swab cultures or stool cultures. The overall sensitivity of rectal swab cultures for detection of VRE was 58 percent in one report but varied directly with VRE density in stool from 100 percent at high densities (≥7.5 logs per gram) to 0 percent at low densities (≤4.5 logs per gram) [<a href="#rid25">25</a>]. Both prior antibiotic exposure and skin colonization with VRE were more common in patients with high stool densities. The authors speculated that the high false-negative rate of rectal swab cultures may contribute to the increasing prevalence of VRE.</p><p>Polymerase chain reaction techniques for identification of <em>vanA</em> and <em>vanB</em> genes from stool/rectal samples have been developed, but their impact on surveillance for VRE has yet to be determined.</p><p>Transmission can occur by both direct contact (eg, the hands of health care workers) and indirectly from environmental surfaces [<a href="#rid26">26</a>]. The following observations come from different studies that have evaluated VRE transmission:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study in which VRE were inoculated in different places, the strains survived for five to seven days on countertops, 24 hours without a reduction in counts on bedrails, 60 minutes on a telephone handpiece, and 30 minutes on the diaphragmatic surface of stethoscopes [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rectal electronic thermometer probes were the means of transmission of VRE in an intensive care unit [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Environmental cultures for VRE were more likely to be positive when the stool density of the organism exceeded four logs per gram [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Health care workers can become colonized in their gastrointestinal tracts, but the rate of acquisition of stool colonization appears to be low and transmission to patients from this source has not been demonstrated [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>There are a number of risk factors for vancomycin-resistant enterococci (VRE) colonization and infection. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Previous antimicrobial therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Patient characteristics</p><p class="bulletIndent1"><span class="glyph">●</span>Colonization pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to contaminated surfaces</p><p class="bulletIndent1"><span class="glyph">●</span>Residence in long-term care facilities</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Previous antimicrobial therapy</span><span class="headingEndMark"> — </span>The most consistently observed risk factor for hospital acquisition of VRE is previous treatment with antimicrobials, particularly <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> and cephalosporins. As an example, a prospective study of 126 adult intensive care units (ICUs) in 60 hospitals found that vancomycin and cephalosporin use were significantly higher in patients with VRE, after controlling for the type of ICU and rates of VRE elsewhere in the institution [<a href="#rid30">30</a>]. In another report, colonization or infection was associated with a longer duration of therapy with <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> (13.2 versus 4.6 days in noninfected controls [<a href="#rid27">27</a>]).</p><p>Use of multiple agents with a broad spectrum of activity may predispose patients to colonization with resistant enterococci, probably via alteration of the normal bowel flora [<a href="#rid31">31</a>]. Among patients with VRE in stool, the administration of antibiotics active against anaerobic organisms can increase the density of stool colonization with VRE, which decreases after discontinuation of these agents [<a href="#rid28">28</a>]. </p><p>Exposure to <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a>, an antibiotic frequently used to treat VRE, can lead to VRE isolates with resistance to <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a> and daptomycin. In one study including more than 80 patients with daptomycin and linezolid non-susceptible VRE, risk factors included recent invasive surgical procedures and daptomycin exposure [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Patient characteristics</span><span class="headingEndMark"> — </span>A number of patient characteristics other than antimicrobial therapy have been associated with a high risk of VRE colonization. These include hospitalization longer than 72 hours, significant underlying medical conditions (end-stage kidney disease requiring dialysis, cancer, transplant recipient), requirement for ICU, proton pump inhibitor use, and invasive devices [<a href="#rid12">12,33</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Colonization pressure</span><span class="headingEndMark"> — </span>Colonization pressure is an important risk factor for acquisition of VRE [<a href="#rid24">24,34</a>]. Colonization pressure in hospitals can lead to substantial increases in VRE colonization. A review of 1039 patients admitted to a general medicine ward demonstrated that colonization with VRE increased from 3.8 percent on admission to 32 percent during hospitalization; 60 percent of the VRE isolates were the same strain [<a href="#rid35">35</a>]. Indeed, hospitalization is strongly correlated with risk of VRE colonization [<a href="#rid35">35,36</a>]. Colonization pressure may outweigh other risk factors including antibiotic use once 50 percent or more of patients within the unit are colonized with VRE.</p><p class="headingAnchor" id="H9"><span class="h3">Exposure to contaminated surfaces</span><span class="headingEndMark"> — </span>Exposure to contaminated surfaces in patient rooms, even after routine discharge cleaning, may be associated with VRE acquisition [<a href="#rid37">37,38</a>]. For example, several outbreaks caused by transmission of VRE from contaminated medical equipment have been reported. Implicated medical equipment included rectal thermometers, tympanic thermometers, and contaminated electrocardiogram leads [<a href="#rid27">27,39,40</a>].</p><p>Transmission of VRE from environmental surfaces to the hands or gloves of health care workers has been well documented. Forty-six percent of health care workers who touched bedrails and bedside tables in rooms of colonized patients in turn contaminated their gloves with VRE in one study [<a href="#rid41">41</a>]. Another study demonstrated that gloves or hands contaminated through contact with contaminated environmental surfaces can transfer VRE to approximately 10 percent of uncontaminated surfaces that are subsequently touched by other health care workers [<a href="#rid42">42</a>]. Patients with VRE colonization are associated with greater environmental contamination than patients with VRE infection [<a href="#rid43">43</a>].</p><p>Specific education of environmental services personnel leads to improved compliance with cleaning protocols and decreased environmental contamination with VRE [<a href="#rid44">44</a>]. A prospective quasi-experimental study showed that improved environmental cleaning significantly reduced the rate of VRE acquisition in a medical ICU [<a href="#rid45">45</a>]. This study was divided into four phases: a baseline period, a period including education to improve cleaning practices, a "washout" period, and a period including a multimodal hand hygiene initiative. Patients were screened for VRE on admission to ICU and daily thereafter. Enhanced cleaning with a detergent-disinfectant was found to reduce environmental and hand contamination as well as VRE acquisition. Novel technologies such as steam vapor [<a href="#rid46">46</a>], UV-C irradiation [<a href="#rid47">47</a>], and vaporized hydrogen peroxide [<a href="#rid48">48</a>] may further decrease environmental contamination and transmission of VRE.</p><p class="headingAnchor" id="H10"><span class="h3">Residence in long-term care facilities</span><span class="headingEndMark"> — </span>Residents of long-term care facilities (LTCFs) appear to be a reservoir for VRE. In a prospective cohort study, 45 percent of patients admitted to an acute care hospital from an LTCF had rectal colonization with VRE; risk factors included prior use of antibiotics and the presence of a decubitus ulcer [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H11"><span class="h1">INFECTION CONTROL</span><span class="headingEndMark"> — </span>Prevention of infection with VRE, as with any multidrug-resistant organism, requires a multifaceted approach including general infection prevention (eg, optimal management of vascular and urinary catheters), accurate and prompt diagnosis and treatment, prudent use of antimicrobial drugs, and prevention of transmission [<a href="#rid50">50</a>]. Methods for prevention will be summarized here.</p><p>Several different strategies for the prevention, control, and eradication of VRE have been studied. These include hand hygiene, contact precautions, cohorting of colonized patients, decolonization, surveillance cultures, and source control.</p><p>Judicious use of antimicrobial drugs (called antimicrobial stewardship) is another modality, but its relative importance for control of VRE is unclear. Agents that would be targeted include <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, third-generation cephalosporins, and anti-anaerobic drugs.</p><p>The majority of published studies on the control of VRE have included multiple bundled approaches. As a result, it is often difficult to determine the attributable efficacy of individual interventions. Judicious use of antimicrobial drugs is another modality, but its relative importance for control of VRE is unclear [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H617037325"><span class="h2">Basic infection prevention principles</span></p><p class="headingAnchor" id="H12"><span class="h3">Hand hygiene</span><span class="headingEndMark"> — </span>Hand hygiene is the most important and most practical means of preventing spread of VRE within the hospital, since VRE is primarily transmitted from patient to patient on the hands of health care workers [<a href="#rid52">52</a>]. Antimicrobial soaps (eg, <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> containing) may be more useful than plain soap for patients with VRE in contact precautions or during an epidemic. Alcohol-based hand rubs are as effective as soap and water and may improve compliance with hand hygiene among health care workers [<a href="#rid53">53</a>].</p><p>The duration of handwashing and the use of soap appear to affect efficacy. This was illustrated in a study in which VRE isolates were placed onto the hands of healthy volunteers [<a href="#rid26">26</a>]. A 30-second wash with water plus soap was necessary to completely eradicate the VRE hand carriage. In contrast, a five-second wash with water alone produced virtually no change in VRE recovery.</p><p>General principles regarding hand hygiene are discussed further separately. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Hand hygiene'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Contact precautions</span><span class="headingEndMark"> — </span>Wearing gown and gloves when entering a patient room and removing them prior to exiting may decrease VRE transmission [<a href="#rid54">54-57</a>]. General principles regarding contact precautions are discussed further separately. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'</a>.)</p><p>The optimal duration of contact precautions for VRE is uncertain and clinical practice is variable. In general, during the first year following VRE infection, we favor documentation of three negative weekly stool or rectal swabs to discontinue contact precautions; if more than one year has passed since VRE infection, we favor one negative stool or rectal swab.</p><p>Guidelines regarding the duration of contact precautions for acute care settings were published by the Society for Healthcare Epidemiology of America (SHEA) [<a href="#rid58">58</a>]. For patients previously infected or colonized with VRE, these guidelines recommend discontinuation of contact precautions after documentation of one to three negative weekly stool or rectal swab surveillance cultures and state that extension of contact precautions is reasonable for patients who are highly immunosuppressed, being treated with broad antibiotic therapy without VRE activity, or receiving care in protected environments (such as burn units) or in institutions with high VRE rates.</p><p>VRE colonization may be prolonged, with high relapse rates after multiple consecutive negative surveillance cultures [<a href="#rid59">59,60</a>]. The sensitivity of stool or rectal swab surveillance cultures for detecting VRE colonization is not well established.</p><p class="headingAnchor" id="H15"><span class="h2">Decolonization</span><span class="headingEndMark"> — </span>No effective methods for decolonization of VRE have been identified, as attempts to eliminate intestinal VRE carriage with nonabsorbable oral antibiotics have been generally disappointing [<a href="#rid61">61-63</a>]. Thus, treatment specifically directed at decolonization of VRE is not recommended.</p><p class="headingAnchor" id="H16"><span class="h2">Surveillance cultures</span><span class="headingEndMark"> — </span>Surveillance cultures for VRE are usually obtained from rectal swabs, perirectal swabs, or stool samples [<a href="#rid51">51,61</a>]. Samples for culture should also be obtained from areas of skin breakdown and draining wounds.</p><p>The standard approach to surveillance of hospitalized patients for VRE carriage consists of active surveillance of patients deemed to be at high risk. (See <a class="local">'Active surveillance of patients at high risk'</a> below.) </p><p>Surveillance cultures are not needed from patients known to have been colonized or infected with VRE within the past 6 to 12 months. Such patients typically remain culture positive regardless of therapy. Clinical cultures should not be used as a surrogate for VRE surveillance cultures due to a lack of correlation [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Rationale</span><span class="headingEndMark"> — </span>The rationale for surveillance cultures to detect VRE carriage is threefold:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients colonized with VRE on admission or during hospitalization are at increased risk for VRE infection in-hospital or after discharge. The rate of infection varies with the health status of the patient, with an increased risk in severely ill or immunocompromised patients [<a href="#rid65">65</a>]. The magnitude of infection risk was assessed in a report from a university hospital over a five-year period [<a href="#rid66">66</a>]. Ninety VRE infections (60 urinary tract, 11 primary bloodstream, and 10 surgical site) occurred in 83 of 1050 patients who were colonized with VRE for an attack rate of 7.9 percent. A similar rate of infection (annual incidence 8.2 percent) was noted in 73 colonized children on a pediatric oncology ward [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VRE colonization may be spread to other patients, most often by health care workers whose hands or gloves have become transiently contaminated [<a href="#rid26">26,52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intervention may reduce both the development of VRE infection and spread to other patients. (See <a class="local">'Impact of infection control'</a> below.)</p><p></p><p class="headingAnchor" id="H18"><span class="h3">Active surveillance of patients at high risk</span><span class="headingEndMark"> — </span>Active surveillance reduces transmission of VRE when performed in outbreak settings [<a href="#rid10">10,66,68,69</a>] or in high-risk patient units such as ICUs and hematology-oncology wards [<a href="#rid70">70-73</a>]. The following observations illustrate the range of findings, some of which included combining surveillance cultures with other infection control measures:</p><p class="bulletIndent1"><span class="glyph">●</span>In an outbreak in the Netherlands, surveillance cultures revealed that 27 patients in six wards were colonized, 93 percent with the outbreak strain [<a href="#rid68">68</a>]. The detection rate of non-outbreak VRE was only about 3 percent, which was comparable to a 2 percent prevalence in nonhospitalized persons. Surveillance cultures with isolation of carriers, preemptive isolation of patients at high risk for VRE colonization, and increased hand hygiene compliance controlled the outbreak. (See <a class="local">'Impact of infection control'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impact of screening hospitalized high-risk patients on admission and then weekly for rectal colonization with VRE was evaluated in 14 units at four academic medical centers in the United States [<a href="#rid73">73</a>]. Ten units were ICUs; the other four cared for immunocompromised and transplant patients. The study population consisted of 8266 admissions and approximately 61,000 patient-days over 165 unit-months. The following findings were noted:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The admission prevalence of VRE colonization varied from 2 to 27 percent, with admission surveillance cultures increasing the detection rate 3.3-fold (range 2- to 17-fold).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The monthly incidence of VRE acquisition was 1 to 10 percent, with weekly surveillance cultures increasing the detection rate 6.1-fold (range 3- to 15-fold).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active surveillance prevented the misclassification of 43 percent of "incident" carriers on the basis of clinical cultures alone and increased precaution days 2.4-fold.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By advancing the initiation of contact precautions, active surveillance consistently reduced VRE transmission over a 12-month period (0.22 percent per month).</p><p></p><p class="headingAnchor" id="H3360375673"><span class="h2">Environmental disinfection</span><span class="headingEndMark"> — </span>VRE can be transmitted to hospitalized patients via contaminated hospital environment. Efforts to improve environmental disinfection decrease this risk. Studies have demonstrated a reduction in VRE acquisition after improving room disinfection through education and performance feedback for environmental services personnel [<a href="#rid74">74</a>]. Enhanced disinfection strategies such as vaporized hydrogen peroxide and ultraviolet (UV) light also reduce the risk of VRE transmission in hospitalized patients. (See  <a class="medical medical_review" href="/d/html/101613.html" rel="external">"Infection prevention: General principles", section on 'Health care environment: Cleaning and disinfection'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Patient bathing</span><span class="headingEndMark"> — </span>Patient bathing with <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> has been shown to be useful for reducing enterococcal colonization and infection; this issue is discussed further separately. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Patient bathing'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Impact of infection control</span><span class="headingEndMark"> — </span>A number of studies have demonstrated the beneficial clinical effects of infection control [<a href="#rid12">12,66,68,72,73,75,76</a>]. The following observations illustrate the potential benefits of infection control measures:</p><p class="bulletIndent1"><span class="glyph">●</span>The impact of screening for VRE on the rate of VRE bacteremia was evaluated in a study of two similar neighboring hospitals, one of which actively screened high-risk patients and one of which did not [<a href="#rid77">77</a>]. Over a six-year period, the hospital that did not screen had a 2.1-fold higher rate of VRE bacteremia (17.1 versus 8.2 per 100,000 hospital days) with a higher incidence of clonally related isolates, suggesting more horizontal transmission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a VRE outbreak in the Netherlands cited above, the outbreak was retrospectively divided into three periods of different infection control measures [<a href="#rid68">68</a>]. The use of alcohol-based hand rubs was enforced during all periods. Period I (duration four months) involved active surveillance cultures, isolation of carriers and cohorting; preemptive isolation of high-risk patients for VRE colonization was added in period II (duration seven months); and cohorting and preemptive isolation were discontinued in period III (duration 18 months). Compared with period I, the relative risk (RR) of detecting epidemic VRE was 0.67 (95% CI, 0.41-1.10) in period II and 0.02 (95% CI, 0.002-0.6) in period III, demonstrating control of the outbreak.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study in an oncology unit in which VRE was endemic, 184 patients received standard infection control measures and 259 received an enhanced infection control strategy [<a href="#rid75">75</a>]. Both regimens included surveillance rectal swab cultures on admission and weekly, handwashing before and after patient contact, and contact precautions for VRE colonized and infected patients. The enhanced regimen included gown and glove use on room entry rather than for patient contact, cohorting with VRE-unknown patients being placed on a separate unit until culture results were available, and more infectious diseases input with emphasis of reducing all antimicrobial drugs. Enhanced infection control was associated with reductions in the incidence of both VRE colonization (10.3 versus 20.7 patients per 1000 patient-days) and VRE bacteremia (0.45 versus 2.1 patients per 1000 patient-days). A side benefit of the program was a significant decrease in the use of all antimicrobial drugs except for <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a system-wide study, a comprehensive infection control intervention was evaluated for the control of endemic colonization and infection in 30 acute care and long-term facilities in Iowa, Nebraska, and South Dakota [<a href="#rid12">12</a>]. The prevalence of VRE colonization fell from 2.2 percent at baseline to 1.4 percent at one year and 0.5 percent at two years after intervention.</p><p></p><p class="headingAnchor" id="H22"><span class="h2">Guideline recommendations</span><span class="headingEndMark"> — </span>The Society for Healthcare Epidemiology of America and the Hospital Infection Control Practices Advisory Committee of the Centers for Disease Control and Prevention published recommendations to prevent transmission of multidrug-resistant organisms, including VRE [<a href="#rid51">51,52</a>].</p><p>Although the two guidelines agree in large part, they offer different recommendations regarding the use of surveillance cultures. The SHEA guideline strongly recommends that facilities implement a program of active surveillance cultures in patients at high risk and contact precautions to reduce the transmission of VRE [<a href="#rid52">52</a>]. In contrast, the HICPAC guideline contains a two-tiered set of recommendations [<a href="#rid51">51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Tier 1–level recommendations, which represent general measures for all health care facilities, do not include the use of active surveillance cultures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tier 2–level recommendations include intensified interventions that should be implemented when the incidence or prevalence of multidrug-resistant organisms such as VRE is not decreasing despite implementation of and adherence to routine control measures. Active surveillance cultures of high-risk patients are recommended as part of Tier 2–level interventions.</p><p></p><p>As described above, the main components of a program aimed at reducing the transmission of VRE in health care facilities include hand hygiene, contact precautions (gloves, gowns, and isolation or cohorting) for infected and colonized patients, active surveillance cultures of patients at high risk, and decontamination of the environment and equipment [<a href="#rid51">51</a>]. In contrast, attempts to eliminate intestinal VRE carriage with nonabsorbable oral antibiotics have been generally disappointing [<a href="#rid61">61-63</a>], and the 2006 HICPAC guidelines concluded that no recommendation for such therapy can be made [<a href="#rid51">51</a>].</p><p>The specific components of these infection control measures and the definition of patients at high risk are similar to those used for the prevention of transmission of MRSA and are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p><p>The only major difference is the site of culture, which, as noted above, consists of rectal, perirectal, or stool cultures as opposed to nares cultures for MRSA surveillance [<a href="#rid51">51</a>]. A mathematical model suggested that, in intensive care units, active surveillance cultures alone could reduce VRE transmission by 39 percent and by 65 percent when combined with preemptive isolation [<a href="#rid72">72</a>]. The 2006 HICPAC guidelines also concluded that the judicious use of <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, third-generation cephalosporins, and anti-anaerobic antibiotics may reduce that rate of VRE colonization [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H4244194506"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115160.html" rel="external">"Society guideline links: Infection control"</a>.)</p><p class="headingAnchor" id="H6898699"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83755.html" rel="external">"Patient education: Vancomycin-resistant enterococci (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions - </strong>Vancomycin-resistant enterococci (VRE) are differentiated from other strains of <em>Enterococcus</em> by an increased minimum inhibitory concentration for <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> and the presence of vancomycin-resistance gene clusters such as <em>vanA</em>. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transmission</strong> – Health care-associated VRE is transmitted on the hands of health care workers; as a result, good hand hygiene is considered an essential measure for reducing the spread of this pathogen. (See <a class="local">'Transmission'</a> above and <a class="local">'Hand hygiene'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Colonization</strong> – Colonization with VRE typically precedes infection. Colonization most commonly occurs in patients with previous antimicrobial therapy and residents in long-term care facilities. Patients who are colonized with VRE have approximately an 8 percent rate of developing a VRE infection in-hospital or after discharge, with a higher rate in patients who are severely ill or immunocompromised. In addition, VRE colonization may be spread to other patients, most often by health care workers whose hands or gloves have become transiently contaminated. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contact precautions</strong> – We recommend that contact precautions be followed for patients with VRE infection or colonization (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Contact precautions'</a> above and  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surveillance cultures</strong> – Routine active surveillance cultures are not warranted to identify patients colonized with VRE in non-epidemic situations. Active surveillance cultures in high-risk patients can be used if the incidence or prevalence of VRE in the facility is not decreasing despite implementation of and rigorous adherence to routine control measures (eg, hand hygiene, contact precautions). (See <a class="local">'Guideline recommendations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decolonization</strong> – We recommend NOT attempting to decolonize VRE carriers (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Decolonization'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing. 32nd edition, CLSI, Wayne, PA 2022.</li><li><a class="nounderline abstract_t">Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157.</a></li><li><a class="nounderline abstract_t">Uttley AH, George RC, Naidoo J, et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989; 103:173.</a></li><li><a class="nounderline abstract_t">Sahm DF, Kissinger J, Gilmore MS, et al. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1989; 33:1588.</a></li><li><a class="nounderline abstract_t">Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994; 32:1148.</a></li><li><a class="nounderline abstract_t">Boyle JF, Soumakis SA, Rendo A, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993; 31:1280.</a></li><li><a class="nounderline abstract_t">Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20:1126.</a></li><li><a class="nounderline abstract_t">Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993; 16:750.</a></li><li><a class="nounderline abstract_t">Karanfil LV, Murphy M, Josephson A, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992; 13:195.</a></li><li><a class="nounderline abstract_t">Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994; 38:1363.</a></li><li><a class="nounderline abstract_t">Rubin LG, Tucci V, Cercenado E, et al. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992; 13:700.</a></li><li><a class="nounderline abstract_t">Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001; 344:1427.</a></li><li><a class="nounderline abstract_t">Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996.</a></li><li><a class="nounderline abstract_t">Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009; 30:184.</a></li><li><a class="nounderline abstract_t">Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med 2020; 382:1309.</a></li><li><a class="nounderline abstract_t">Surveillance CNI. Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014-2018. Can Commun Dis Rep 2020; 46:99.</a></li><li><a class="nounderline abstract_t">Miranda AG, Singh KV, Murray BE. DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool. J Clin Microbiol 1991; 29:2752.</a></li><li><a class="nounderline abstract_t">Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995; 123:250.</a></li><li><a class="nounderline abstract_t">Piezzi V, Wassilew N, Atkinson A, et al. Nosocomial outbreak of vancomycin-resistant Enterococcus faecium (VRE) ST796, Switzerland, 2017 to 2020. Euro Surveill 2022; 27.</a></li><li><a class="nounderline abstract_t">Bender JK, Hermes J, Zabel LT, et al. Controlling an Unprecedented Outbreak with Vancomycin-Resistant Enterococcus faecium in Germany, October 2015 to November 2019. Microorganisms 2022; 10.</a></li><li><a class="nounderline abstract_t">Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.</a></li><li><a class="nounderline abstract_t">Willems RPJ, van Dijk K, Vehreschild MJGT, et al. Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis. Lancet Infect Dis 2023; 23:719.</a></li><li><a class="nounderline abstract_t">DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005; 41:327.</a></li><li><a class="nounderline abstract_t">Bonten MJ, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998; 158:1127.</a></li><li><a class="nounderline abstract_t">D'Agata EM, Gautam S, Green WK, Tang YW. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin Infect Dis 2002; 34:167.</a></li><li><a class="nounderline abstract_t">Noskin GA, Stosor V, Cooper I, Peterson LR. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol 1995; 16:577.</a></li><li><a class="nounderline abstract_t">Livornese LL Jr, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992; 117:112.</a></li><li><a class="nounderline abstract_t">Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343:1925.</a></li><li><a class="nounderline abstract_t">Baran J Jr, Ramanathan J, Riederer KM, Khatib R. Stool colonization with vancomycin-resistant enterococci in healthcare workers and their households. Infect Control Hosp Epidemiol 2002; 23:23.</a></li><li><a class="nounderline abstract_t">Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001; 135:175.</a></li><li><a class="nounderline abstract_t">Weinstein JW, Roe M, Towns M, et al. Resistant enterococci: a prospective study of prevalence, incidence, and factors associated with colonization in a university hospital. Infect Control Hosp Epidemiol 1996; 17:36.</a></li><li><a class="nounderline abstract_t">Greene MH, Harris BD, Nesbitt WJ, et al. Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus. Open Forum Infect Dis 2018; 5:ofy185.</a></li><li><a class="nounderline abstract_t">Chanderraj R, Millar JA, Patel TS, et al. Vancomycin-Resistant Enterococcus Acquisition in a Tertiary Care Hospital: Testing the Roles of Antibiotic Use, Proton Pump Inhibitor Use, and Colonization Pressure. Open Forum Infect Dis 2019; 6:ofz139.</a></li><li><a class="nounderline abstract_t">Alevizakos M, Gaitanidis A, Nasioudis D, et al. Colonization With Vancomycin-Resistant Enterococci and Risk for Bloodstream Infection Among Patients With Malignancy: A Systematic Review and Meta-Analysis. Open Forum Infect Dis 2017; 4:ofw246.</a></li><li><a class="nounderline abstract_t">Cohen MJ, Adler A, Block C, et al. Acquisition of vancomycin-resistant enterococci in internal medicine wards. Am J Infect Control 2009; 37:111.</a></li><li><a class="nounderline abstract_t">Riedel S, Von Stein D, Richardson K, et al. Development of a prediction rule for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus carriage in a Veterans Affairs Medical Center population. Infect Control Hosp Epidemiol 2008; 29:969.</a></li><li><a class="nounderline abstract_t">Martínez JA, Ruthazer R, Hansjosten K, et al. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905.</a></li><li><a class="nounderline abstract_t">Trillis F 3rd, Eckstein EC, Budavich R, et al. Contamination of hospital curtains with healthcare-associated pathogens. Infect Control Hosp Epidemiol 2008; 29:1074.</a></li><li><a class="nounderline abstract_t">Falk PS, Winnike J, Woodmansee C, et al. Outbreak of vancomycin-resistant enterococci in a burn unit. Infect Control Hosp Epidemiol 2000; 21:575.</a></li><li><a class="nounderline abstract_t">Porwancher R, Sheth A, Remphrey S, et al. Epidemiological study of hospital-acquired infection with vancomycin-resistant Enterococcus faecium: possible transmission by an electronic ear-probe thermometer. Infect Control Hosp Epidemiol 1997; 18:771.</a></li><li><a class="nounderline abstract_t">Ray AJ, Hoyen CK, Taub TF, et al. Nosocomial transmission of vancomycin-resistant enterococci from surfaces. JAMA 2002; 287:1400.</a></li><li><a class="nounderline abstract_t">Duckro AN, Blom DW, Lyle EA, et al. Transfer of vancomycin-resistant enterococci via health care worker hands. Arch Intern Med 2005; 165:302.</a></li><li><a class="nounderline abstract_t">Knelson LP, Williams DA, Gergen MF, et al. A comparison of environmental contamination by patients infected or colonized with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a multicenter study. Infect Control Hosp Epidemiol 2014; 35:872.</a></li><li><a class="nounderline abstract_t">Hota B, Blom DW, Lyle EA, et al. Interventional evaluation of environmental contamination by vancomycin-resistant enterococci: failure of personnel, product, or procedure? J Hosp Infect 2009; 71:123.</a></li><li><a class="nounderline abstract_t">Hayden MK, Bonten MJ, Blom DW, et al. Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures. Clin Infect Dis 2006; 42:1552.</a></li><li><a class="nounderline abstract_t">Tanner BD. Reduction in infection risk through treatment of microbially contaminated surfaces with a novel, portable, saturated steam vapor disinfection system. Am J Infect Control 2009; 37:20.</a></li><li><a class="nounderline abstract_t">Al Yacoub AN, Gauly M, Holtz W. Is sucrose required in open pulled straw (OPS) vitrification of mouse embryos? Cryo Letters 2013; 34:466.</a></li><li><a class="nounderline abstract_t">Passaretti CL, Otter JA, Reich NG, et al. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. Clin Infect Dis 2013; 56:27.</a></li><li><a class="nounderline abstract_t">Elizaga ML, Weinstein RA, Hayden MK. Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci. Clin Infect Dis 2002; 34:441.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Vancomycin-resistant enterococci (VRE) in healthcare settings. https://www.cdc.gov/hai/organisms/vre/vre.html (Accessed on January 17, 2023).</li><li class="breakAll">Centers for Disease Control and Prevention. Management of multidrug-resistant organisms in healthcare settings, 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf (Accessed on January 17, 2023).</li><li><a class="nounderline abstract_t">Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24:362.</a></li><li><a class="nounderline abstract_t">Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1.</a></li><li><a class="nounderline abstract_t">Muñoz Torres E, Abad Hernández MM, López Bravo A, et al. [Effect of (+) cyanidanol-3 on experimental liver cirrhosis induced by carbon tetrachloride]. An Med Interna 1989; 6:189.</a></li><li><a class="nounderline abstract_t">Puzniak LA, Leet T, Mayfield J, et al. To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci. Clin Infect Dis 2002; 35:18.</a></li><li><a class="nounderline abstract_t">Srinivasan A, Song X, Ross T, et al. A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit. Infect Control Hosp Epidemiol 2002; 23:424.</a></li><li><a class="nounderline abstract_t">Slaughter S, Hayden MK, Nathan C, et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1996; 125:448.</a></li><li><a class="nounderline abstract_t">Banach DB, Bearman G, Barnden M, et al. Duration of Contact Precautions for Acute-Care Settings. Infect Control Hosp Epidemiol 2018; 39:127.</a></li><li><a class="nounderline abstract_t">Baden LR, Thiemke W, Skolnik A, et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance". Clin Infect Dis 2001; 33:1654.</a></li><li><a class="nounderline abstract_t">Donskey CJ, Hoyen CK, Das SM, et al. Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002; 23:436.</a></li><li><a class="nounderline abstract_t">Weber SG, Huang SS, Oriola S, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol 2007; 28:249.</a></li><li><a class="nounderline abstract_t">Mondy KE, Shannon W, Mundy LM. Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2001; 33:473.</a></li><li><a class="nounderline abstract_t">Hachem R, Raad I. Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2002; 23:43.</a></li><li><a class="nounderline abstract_t">Leekha S, O'Hara LM, Sbarra A, et al. Comparison of surveillance and clinical cultures to measure the impact of infection control interventions on the incidence of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in the hospital. Infect Control Hosp Epidemiol 2020; 41:161.</a></li><li><a class="nounderline abstract_t">Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc 2006; 81:529.</a></li><li><a class="nounderline abstract_t">Calfee DP, Giannetta ET, Durbin LJ, et al. Control of endemic vancomycin-resistant Enterococcus among inpatients at a university hospital. Clin Infect Dis 2003; 37:326.</a></li><li><a class="nounderline abstract_t">Henning KJ, Delencastre H, Eagan J, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996; 15:848.</a></li><li><a class="nounderline abstract_t">Mascini EM, Troelstra A, Beitsma M, et al. Genotyping and preemptive isolation to control an outbreak of vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2006; 42:739.</a></li><li><a class="nounderline abstract_t">Singh N, Léger MM, Campbell J, et al. Control of vancomycin-resistant enterococci in the neonatal intensive care unit. Infect Control Hosp Epidemiol 2005; 26:646.</a></li><li><a class="nounderline abstract_t">Hachem R, Graviss L, Hanna H, et al. Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with hematologic malignancy. Infect Control Hosp Epidemiol 2004; 25:391.</a></li><li><a class="nounderline abstract_t">Siddiqui AH, Harris AD, Hebden J, et al. The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide. Am J Infect Control 2002; 30:40.</a></li><li><a class="nounderline abstract_t">Perencevich EN, Fisman DN, Lipsitch M, et al. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004; 38:1108.</a></li><li><a class="nounderline abstract_t">Huang SS, Rifas-Shiman SL, Pottinger JM, et al. Improving the assessment of vancomycin-resistant enterococci by routine screening. J Infect Dis 2007; 195:339.</a></li><li><a class="nounderline abstract_t">Mitchell BG, Hall L, White N, et al. An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial. Lancet Infect Dis 2019; 19:410.</a></li><li><a class="nounderline abstract_t">Montecalvo MA, Jarvis WR, Uman J, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999; 131:269.</a></li><li><a class="nounderline abstract_t">May AK, Melton SM, McGwin G, et al. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock 2000; 14:259.</a></li><li><a class="nounderline abstract_t">Price CS, Paule S, Noskin GA, Peterson LR. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003; 37:921.</a></li></ol></div><div id="topicVersionRevision">Topic 4045 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing. 32nd edition, CLSI, Wayne, PA 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2968517" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2506070" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : High-level vancomycin-resistant enterococci causing hospital infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2554802" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8051238" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501230" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619987" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329505" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593099" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092838" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1289397" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Vancomycin-resistant Enterococcus faecium in hospitalized children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11346807" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Control of vancomycin-resistant enterococcus in health care facilities in a region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18947320" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19125679" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32242356" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32558807" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1757545" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611590" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36695463" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nosocomial outbreak of vancomycin-resistant Enterococcus faecium (VRE) ST796, Switzerland, 2017 to 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36014021" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Controlling an Unprecedented Outbreak with Vancomycin-Resistant Enterococcus faecium in Germany, October 2015 to November 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15306996" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36731484" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007529" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9605785" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740703" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8568202" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1605425" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136263" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11868888" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Stool colonization with vancomycin-resistant enterococci in healthcare workers and their households.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487484" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8789685" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Resistant enterococci: a prospective study of prevalence, incidence, and factors associated with colonization in a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30320147" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31024976" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vancomycin-Resistant Enterococcus Acquisition in a Tertiary Care Hospital: Testing the Roles of Antibiotic Use, Proton Pump Inhibitor Use, and Colonization Pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480243" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Colonization With Vancomycin-Resistant Enterococci and Risk for Bloodstream Infection Among Patients With Malignancy: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18986736" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acquisition of vancomycin-resistant enterococci in internal medicine wards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18702599" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Development of a prediction rule for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus carriage in a Veterans Affairs Medical Center population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12963563" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823274" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Contamination of hospital curtains with healthcare-associated pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001260" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Outbreak of vancomycin-resistant enterococci in a burn unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9397374" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Epidemiological study of hospital-acquired infection with vancomycin-resistant Enterococcus faecium: possible transmission by an electronic ear-probe thermometer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11903026" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nosocomial transmission of vancomycin-resistant enterococci from surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710793" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Transfer of vancomycin-resistant enterococci via health care worker hands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24915217" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A comparison of environmental contamination by patients infected or colonized with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19108932" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Interventional evaluation of environmental contamination by vancomycin-resistant enterococci: failure of personnel, product, or procedure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16652312" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18834748" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Reduction in infection risk through treatment of microbially contaminated surfaces with a novel, portable, saturated steam vapor disinfection system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24448766" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Is sucrose required in open pulled straw (OPS) vitrification of mouse embryos?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23042972" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11797169" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11797169" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11797169" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12785411" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12418624" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2491520" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : [Effect of (+) cyanidanol-3 on experimental liver cirrhosis induced by carbon tetrachloride].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12060870" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186206" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8779456" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29321078" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Duration of Contact Precautions for Acute-Care Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11595985" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186208" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17326014" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11462182" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11868893" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31896372" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparison of surveillance and clinical cultures to measure the impact of infection control interventions on the incidence of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in the hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610573" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vancomycin-resistant enterococci: colonization, infection, detection, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12884155" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Control of endemic vancomycin-resistant Enterococcus among inpatients at a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8895914" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16477546" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Genotyping and preemptive isolation to control an outbreak of vancomycin-resistant Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16092746" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Control of vancomycin-resistant enterococci in the neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188844" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11852415" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095215" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205471" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Improving the assessment of vancomycin-resistant enterococci by routine screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30858014" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10454948" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11028540" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13130403" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
